Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
161.7 USD | -0.57% | -3.62% | +4.36% |
30/04 | Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent | MT |
29/04 | Health Care Up on Growth Optimism -- Health Care Roundup | DJ |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Sales forecast by analysts have been recently revised upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company is in debt and has limited leeway for investment
- With an expected P/E ratio at 30.94 and 24 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.36% | 286B | C+ | ||
+33.25% | 699B | C+ | ||
+25.41% | 571B | B | ||
-3.55% | 364B | C+ | ||
+18.16% | 326B | B- | ||
+14.89% | 236B | B+ | ||
+5.59% | 198B | B- | ||
-9.33% | 194B | A+ | ||
-3.69% | 149B | C+ | ||
-5.59% | 154B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ABBV Stock
- Ratings AbbVie Inc.